CARDIOTOSSICITà IN PAZIENTI ANZIANE CON CANCRO DELLA MAMMELLA IN TRATTAMENTO CON TRASTUZUMAB

objective. TRASTUZUMAB, A HUMANIZED MONOCLONAL ANTIBODY DIRECTED AGAINST HER2, IS INDICATED FOR PATIENTS WITH HER2 POSITIVE EARLY BREAST CANCER (EBC)OR METASTATIC BREAST CANCER (MBC). SEVERAL STUDIES SHOWED AN INCREASED RISK OF CARDIOTOXICITY IN PATIENTS TREATED WITH TRASTUZUMAB. THE AIM OF OUR STUDY WAS TO EVALUATE ANY CARDIAC EFFECTS IN PATIENTS TREATED WITH TRASTUZUMAB FOR EBC OR MBC. methods.FROM JANUARY 2007 TO MARCH 2009, WE EVALUATED 27 PATIENTS (15<70 YEARS AND 12>70YEARS) WITH EBC IN ADJUVANT TREATMENT WITH TRASTUZUMAB , AFTER CHEMIOTHERAPY WITH ANTHRACYCLINES AND TAXANES, AND 24 PATIENTS(13<70YEARSAND 11 >70YEARS) WITH MBC IN TREATMENT WITH CHEMOTHERAPY AND TRASTUZUMAB. CARDIAC EVENTS WERE DWFINED AS ASYMPTOMATIC (LVEF>50% WITH DECREASE >10% RELATIVE TO BASELINE) OR SYMPTOMATIC (GRADE 3OR4 LEFT VENTRICULAR SYSTOLIC DYSFUNCTION)ACCORDING TO THE NATIONAL CANCER INSTITUTE COMMON TERMONILOGY CRITERIA FOR ADVERSE EVENTS (NCI-CTCAE V3.0.) CARDIAC FUNCTION WAS ASSESED EVERY 3 MONTHS BY ECHOCARDIOGRAM WITH LVEF. results.IN EBC GROUP, 2 PATIENTS>70 YEARS AND 2 >70 YEARS PRESENTED AN ASYMPTOMATIC CARDIAC EVENT. IN MBC GROUP, 2 PATIENTS<70 YEARS AND 3>70 YEARS PRESENTED AN ASYMPTOMATIC CARDIAC EVENT. IN MBC GROUP, 2 PATIENTS<70 YEARS AND 3> 70YEARS PRESENTED AN ASYMPTOMATIC CARDIAC EVENTS. ONE PATIENT (AGED >70 YEARS) WITH METASTATIC DISEASE PRESENTED A GRADE 3 LEFT VENTRICULAR SYSTOLIC DYSFUNCTION. conclusion. OUR STUDY SHOWS THAT CARDIAC EVENTS RELATED TO THE ADMINISTRATION OF TRASTUZUMAB ARE USUALLY ASYMPTOMATIC, CAUSE A REVERSIBLE DECREASE IN LVEF AND OCCUR MORE FREQUENTLY IN PATIENT AGED >70YEARS, WITH A LOWER LVEF PRIOR TO TREATMENT.